Gni Group Ltd. · TSE:2160

Gni — Q2 2020 Earnings Presentation

8 slides from Gni's earnings presentation, Aug 18, 2020

  1. Slide 1: GNI Group Ltd. Q2 FY2020 Financial Results

    GNI Group Ltd. Q2 FY2020 Financial Results Corporate Presentation August 18, 2020 We Bring New Hope to Patients Securities Code: 2160

  2. Slide 2: Forward-looking Statements

    We Bring New Hope to Patients Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are for

  3. Slide 3: FY2020 – Q2 Highlights

    We Bring New Hope to Patients FY2020 – Q2 Highlights Higher sales and profits GNI Group Ltd. continued to execute its business plan in Q2 and achieved year-over-year revenue and profit growth, while managing the evolving impact of the global COVID-19 pandemic on the Group’s various operations. Pharm

  4. Slide 4: FY2020-Q2 Consolidated Financial Results Comparison (YoY)

    We Bring New Hope to Patients FY2020-Q2 Consolidated Financial Results Comparison (YoY) Million yen : Amounts of less than one million yen are rounded down FY2019 FY2020 Revenue & Gross Profit Statement of Income Jan.-June Jan.-June Change Continued upward sales performance of the pharmaceutical Rev

  5. Slide 5: Revenue Growth Trend

    We Bring New Hope to Patients Revenue Growth Trend 82.42% 3-Year Compounded Annual Growth Rate Index:2017 Q1 Revenue =100 800 Started New production factory construction for BC* 700 Contributed additional sales 644 Achieved a key milestone with 603 607 the inclusion of Etuary® in and profits to GNI

  6. Slide 6: Development: Pipeline Update

    We Bring New Hope to Patients Development : Pipeline Update Product - Indication Origin Phase I Phase II Phase III Latest Status Etuary® (China) - Connective Tissue Disease Associated Dual Phase III clinical trials ongoing. Due to the COVID-19 pandemic, Proprietary Interstitial Lung Disease (CTD-ILD

  7. Slide 7: Research: Ongoing Projects

    We Bring New Hope to Patients Research : Ongoing Projects (uSMITE™) Cullgen Novel E3 Targeting the development of innovative new chemical binders based on entities (NCEs) for the novel treatment of cancer as well Unique the viral linker hijacking as inflammatory and autoimmune diseases, utilizing it

  8. Slide 8: Contact Information

    We Bring New Hope to Patients Contact Information infojapan@gnipharma.com © 2020 GNI Group Ltd. All rights reserved 8

GNI Group — Q2 2020 Earnings Presentation on 6ix